

# Alexandria T Phan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3809730/publications.pdf>

Version: 2024-02-01

15  
papers

6,731  
citations

1170033

9  
h-index

1181555

14  
g-index

15  
all docs

15  
docs citations

15  
times ranked

6376  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroendocrine Tumors: a Relevant Clinical Update. <i>Current Oncology Reports</i> , 2022, 24, 703-714.	1.8	9
2	Exploration of machine learning techniques to examine the journey to neuroendocrine tumor diagnosis with real-world data. <i>Future Oncology</i> , 2021, 17, 3217-3230.	1.1	2
3	Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 695-703.	5.1	111
4	Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. <i>New England Journal of Medicine</i> , 2014, 371, 224-233.	13.9	1,460
5	Metastatic pancreatic neuroendocrine tumors (pNET): Placing current findings into perspective. <i>Cancer Treatment Reviews</i> , 2013, 39, 3-9.	3.4	9
6	Relief of bowel-related symptoms with telotristat etiprate in octreotide refractory carcinoid syndrome: Preliminary results of a placebo-controlled, multicenter study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 312-312.	0.8	2
7	NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. <i>Pancreas</i> , 2010, 39, 784-798.	0.5	161
8	One Hundred Years After "Carcinoid": Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. <i>Journal of Clinical Oncology</i> , 2008, 26, 3063-3072.	0.8	3,875
9	Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 4311-4318.	0.8	622
10	Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b. <i>Journal of Clinical Oncology</i> , 2008, 26, 1316-1323.	0.8	417
11	Neuroendocrine tumors: novel approaches in the age of targeted therapy. <i>Oncology</i> , 2008, 22, 1617-23; discussion 1623-4, 1629.	0.4	7
12	Adrenal Cortical Carcinoma"Review of Current Knowledge and Treatment Practices. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 489-507.	0.9	35
13	Small Cell Carcinomas of the Gastrointestinal Tract. , 2006, , 430-435.		2
14	Gastric carcinoma. <i>Current Oncology Reports</i> , 2004, 6, 192-198.	1.8	8
15	Advances in neoadjuvant chemotherapy in soft tissue sarcomas. <i>Current Treatment Options in Oncology</i> , 2003, 4, 433-439.	1.3	11